Stock Market Reviews

MRSN (Mersana Therapeutics, Inc.) News

Get the latest news, insights, and market updates on MRSN (Mersana Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates
  Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 12, 2025 - $MRSN
• Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
  CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2025 on Friday, November 14, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time tha
  Nov 10, 2025 - $MRSN
• Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates
  Curis (CRIS) delivered earnings and revenue surprises of +20.97% and +8.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025 - $MRSN
• Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates
  Royalty Pharma (RPRX) delivered earnings and revenue surprises of +5.41% and +1.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $MRSN
• Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?
  The mean of analysts' price targets for Mersana Therapeutics (MRSN) points to a 314.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Sep 8, 2025 - $MRSN
• Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet
  The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Mersana Therapeutics (MRSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  Aug 22, 2025 - $MRSN
• Mersana Therapeutics Second Quarter 2025 Earnings: Misses Expectations
  Mersana Therapeutics ( NASDAQ:MRSN ) Second Quarter 2025 Results Key Financial Results Revenue: US$3.06m (up 33% from...
  Aug 15, 2025 - $MRSN
• Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
  Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 13, 2025 - $MRSN
• Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results
  More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting can
  Aug 13, 2025 - $MRSN
• Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
  Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +29.82% and +181.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 12, 2025 - $MRSN